SEARCH:   Advanced

Blood, 15 August 2008, Vol. 112, No. 4, pp. 1035-1038. Prepublished online as a Blood First Edition Paper on May 23, 2008; DOI 10.1182/blood-2008-02-140954. This Article Full Text (PDF) All Versions of this Article: blood-2008-02-140954v1 112/4/1035    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by van Rhee, F. Articles by Barlogie, B. Search for Related Content PubMed PubMed Citation Articles by van Rhee, F. Articles by Barlogie, B. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 22, 2008 Accepted April 1, 2008 First thalidomide clinical trial in multiple myeloma: a decade later Frits van Rhee, John D. Shaughnessy, Jr., Elias Anaissie, David Siegel, Antje Hoering, Jerome Zeldis, Bonnie Jenkins, Seema Singhal, Jayesh Mehta, John Crowley, Sundar Jagannath, and Bart Barlogie* Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock Hackensack University, Hackensack, NJ Cancer Research and Biostatistics, CRAB, Seattle Celgene Corporation, Celgene Corporation, Cambridge Northwestern University, Chicago, IL St. Vincent's Hospital, New York, NY * Corresponding author; email: barlogiebart{at}uams.edu. The clinical outcomes of 169 patients, enrolled in the first clinical trial of thalidomide for advanced or refractory myeloma, are updated. Seventeen patients remain alive and 10 event-free, with a median follow-up of 9.2 years. According to multivariate analysis of pre-treatment variables, cytogenetic abnormalities (CA), present in 47% of patients within 3 months of enrollment, and lambda light chain isotype both affected overall survival and event-free survival adversely. Forty percent of the 58 patients lacking these 2 unfavorable features, one-half of whom had no disease recurrence, survived at least 6 years, in contrast to fewer than 5% among those with 1 or 2 risk features (P<0.0001). Patients who had received cumulative thalidomide doses in excess of 42g in the first 3 months enjoyed superior overall and event-free survival. The poor outcome associated with lambda-type myeloma may relate to its over-representation in molecularly defined high-risk disease gleaned from studies in newly diagnosed myeloma. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Reece, J.-L. Harousseau, and M. A. Gertz Nontransplant Therapy of Myeloma, High-dose Therapy for Myeloma, and a Personalized Care Plan for Treatment of Myeloma ASCO Educational Book, January 1, 2009; 2009(1): 502 - 509. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020